Organization | Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Glasgow United Kingdom (1999)

Organization Overview

First Clinical Trial

2008

NCT00804154

First Marketed Drug

2018

lidocaine (xylocaine)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sorrento Therapeutics | Sorrento Therapeutics, Inc. | Virttu Biologics Limited

Active Ingredients

Marketed Drugs (3)

Key: Sorrento Therapeutics, Inc. (2) Acquired (1)

celecoxib (celebrex) (2020)

colchicine (colbenemid) (2019)

lidocaine (xylocaine) (2018)

Drugs in Phase 4 Trials (1)

Key: Sorrento Therapeutics, Inc. (0) Acquired (1)

lidocaine (xylocaine) (12 trials)

Drugs in Phase 3 Trials (13)

Key: Sorrento Therapeutics, Inc. (8) Acquired (5)

abivertinib (4 trials)

capecitabine (xeloda) (1 trial)

capsaicin (qutenza) (8 trials)

cea car-t cells (2 trials)

cisplatin (platinol) (1 trial)

dexamethasone (2 trials)

fluorouracil (efudex) (1 trial)

gefitinib (iressa) (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

paclitaxel (taxol) (2 trials)

sti-1558 (6 trials)

Drugs in Phase 2 Trials (10)

Key: Sorrento Therapeutics, Inc. (8) Acquired (2)

abiraterone (zytiga) (1 trial)

ac0010ma (7 trials)

allogeneic adipose derived mesenchymal stem cell (6 trials)

covi-amg (4 trials)

covi-drops (3 trials)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 1 Trials (17)

Key: Sorrento Therapeutics, Inc. (10) Acquired (7)

ac0058ta (2 trials)

anti-cea designer t cells (1 trial)

car2 anti-cd38 a2 car-t cells (1 trial)

etanercept (enbrel) (1 trial)

fluorapacin (1 trial)

itraconazole (sporanox) (1 trial)

menthol (Salonpas) (1 trial)

naltrexone (revia) (2 trials)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 1)

Amyloidosis (Phase 1)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Ascites (Phase 1)

Biliary Tract Neoplasms (Phase 2)

Cancer Pain (Phase 3)

Carcinoma (Phase 1)

Immunoglobulin Light-chain Amyloidosis (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 1)

Mycoses (Phase 1)

Mycosis Fungoides (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain, Intractable (Phase 3)

Pancreatic Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 81
# of Trial APIs: 41